Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Industry Valuation for the Spinal Muscular Atrophy Treatment Sector?

The market for treatment of spinal muscular atrophy has been developing at an increased rate in the past few years. It is projected to expand from a worth of $4.41 billion in 2024 to a value of $5.1 billion in 2025, with a compound annual growth rate (CAGR) of 15.7%. This considerable growth in the historic phase can be accredited to factors such as a rise in the cases of spinal muscular atrophy, increasing approval for new gene therapy methods, growing cognizance for early detection and treatment, increment in research and development ventures, and the rising provision of newborn screening practices.

Rapid expansion is anticipated for the spinal muscular atrophy treatment market, with forecasts indicating it will swell to $9.02 billion by 2029, growing at a compound annual growth rate (CAGR) of 15.3%. Factors contributing to this growth during the forecast period include the escalating prevalence of spinal muscular atrophy, the surge in approved, innovative gene therapies, and heightened awareness for early diagnosis and treatment. Additionally, increased investment in research and development coupled with wider reach of newborn screening programs also play a part. Future trends include gene therapy advancement, the inclusion of personalized medicine methods, technologically advanced development of oral treatments, enhancement in newborn screening approaches, and progress in combined therapeutic methodologies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24714&type=smp

What Forces Are Driving The Growth Of The Spinal Muscular Atrophy Treatment Market?

As interest in gene therapy intensifies, the spinal muscular atrophy treatment market is projected to expand. Gene therapy, a medical method that manipulates a person’s genetic material (either DNA or RNA) to treat or prevent diseases, is increasingly seen as a potential way to directly modify or replace defective genes. This can address the root cause of genetic disorders, offering more long-lasting or permanent therapeutic effects as opposed to conventional treatments. Gene therapy techniques like onasemnogene abeparvovec (Zolgensma) are beneficial for spinal muscular atrophy treatments, providing a one-time, targeted strategy that delivers a functional copy of the SMN1 gene. This significantly enhances motor function and life quality for individuals with SMA. Notably, the American Society of Gene and Cell Therapy reported in January 2024 that the number of gene therapies in Phase III trials rose by 10% in the last quarter of 2023 from the previous quarter, marking the first increase since the third quarter of 2022. Hence, the escalating attention on gene therapy is aiding the growth of the spinal muscular atrophy treatment market.

How Is The Spinal Muscular Atrophy Treatment Industry Segmented Across Key Parameters?

The spinal muscular atrophy treatment market covered in this report is segmented –

1) By Treatment: Medication, Physical Therapy, Surgery, Other Treatments

2) By Type: Werdnig-Hoffmann Disease, Infant Spinal Muscular Atrophy, Kugelberg-Welander Disease, Adult Spinal Muscular Atrophy

3) By Route Of Administration: Oral, Parenteral

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Medication: Nusinersen (Spinraza), Onasemnogene Abeparvovec-Xioi (Zolgensma), Risdiplam (Evrysdi), Antisense Oligonucleotides, Spinal Muscular Atrophy (SMN2) Splicing Modifiers, Corticosteroids, Supportive Medications

2) By Physical Therapy: Occupational Therapy, Respiratory Therapy, Aquatic Therapy, Orthotic Support, Assistive Mobility Devices, Range-Of-Motion Exercises

3) By Surgery: Spinal Fusion Surgery, Scoliosis Correction Surgery, Orthopedic Surgery, Gastrostomy Tube Placement, Tracheostomy

4) By Other Treatments: Nutritional Support, Respiratory Support, Psychosocial Support And Counseling, Genetic Counseling, Stem Cell Therapy

What Notable Trends Are Shaping The Direction Of The Spinal Muscular Atrophy Treatment Market?

Prominent businesses in the spinal muscular atrophy treatment market are concentrating their efforts on producing innovative versions like survival motor neuron 2 (SMN2) splicing modifier tablets. These potent new drugs are designed to amplify motor function and slow the advancement of the disease. Specifically designed for oral consumption, these SMN2 splicing modifier tablets alter the SMN2 gene’s splicing, thus producing functional SMN protein which is a crucial component for the survival of motor neurons. The tablets play a significant role in treating spinal muscular atrophy (SMA) by boosting the amounts of full-length SMN protein, leading to an improvement in muscle function and stabilizing the progression of the ailment. In February 2025, an example of this was when Genentech, Inc., a biotechnology company based in the United States, was granted approval for its Evrysdi (risdiplam) tablet by the U.S. Food and Drug Administration. This was the first and sole non-invasive SMN2 splicing modifier tablet introduced for treating SMA. The Evrysdi tablet is as effective and safe as the current oral solution, plus it brings added benefits such as storage at room temperature and simplified usage for individuals aged two years or over who weigh above 44 lbs (20 kgs), providing increased convenience and adaptability in the management of the disease.

Which Companies Currently Dominate The Competitive Landscape In The Spinal Muscular Atrophy Treatment Industry?

Major companies operating in the spinal muscular atrophy treatment market are F. Hoffmann-La Roche Ltd, Novartis AG, Biogen Inc., Chugai Pharmaceutical Co. Ltd, PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Ultragenyx Pharmaceutical Inc., Catalyst Pharmaceuticals Inc., BIOCAD INDIA PRIVATE LIMITED, Cytokinetics Incorporated, Voyager Therapeutics Inc., Scholar Rock Holding Corporation, Genethon, Exegenesis Bio Inc, NMD Pharma A/S, Biohaven Pharmaceutical Holding Company Ltd, Alcyone Therapeutics Inc., Vybion Inc., Apteeus SAS, Biophytis SA, Ractigen Therapeutics.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/spinal-muscular-atrophy-treatment-global-market-report

Which Geographic Regions Are Driving Demand In The Spinal Muscular Atrophy Treatment Market?

North America was the largest region in the spinal muscular atrophy treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spinal muscular atrophy treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24714&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model